NasdaqGS:MEDP

Stock Analysis Report

Executive Summary

Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide.

Snowflake

Fundamentals

Excellent balance sheet with proven track record.


Similar Companies

Share Price & News

How has Medpace Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.0%

MEDP

1.5%

US Life Sciences

1.8%

US Market


1 Year Return

48.6%

MEDP

12.1%

US Life Sciences

7.3%

US Market

Return vs Industry: MEDP exceeded the US Life Sciences industry which returned 12.1% over the past year.

Return vs Market: MEDP exceeded the US Market which returned 7.3% over the past year.


Shareholder returns

MEDPIndustryMarket
7 Day-1.0%1.5%1.8%
30 Day-8.0%-3.7%-0.7%
90 Day24.9%-3.8%0.06%
1 Year48.6%48.6%12.3%12.1%9.7%7.3%
3 Year149.0%149.0%77.4%76.0%46.3%36.9%
5 Yearn/a113.8%104.1%64.5%46.5%

Price Volatility Vs. Market

How volatile is Medpace Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Medpace Holdings undervalued compared to its fair value and its price relative to the market?

31.45x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Undervalued: MEDP ($77.94) is trading above our estimate of fair value ($58.17)

Significantly Undervalued: MEDP is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MEDP is good value based on its PE Ratio (31.5x) compared to the Life Sciences industry average (32.6x).

PE vs Market: MEDP is poor value based on its PE Ratio (31.5x) compared to the US market (17.7x).


Price to Earnings Growth Ratio

Low PEG Ratio: MEDP is poor value based on its PEG Ratio (2.3x)


Price to Book Ratio

PB vs Industry: MEDP is good value based on its PB Ratio (4.2x) compared to the US Life Sciences industry average (4.6x).


Next Steps

Future Growth

How is Medpace Holdings forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

13.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MEDP's forecast earnings growth (13.9% per year) is above the savings rate (2.7%).

Earnings vs Market: MEDP's earnings (13.9% per year) are forecast to grow slower than the US market (14.6% per year).

High Growth Earnings: MEDP's earnings are forecast to grow, but not significantly.

Revenue vs Market: MEDP's revenue (11.3% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: MEDP's revenue (11.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: MEDP's Return on Equity is forecast to be low in 3 years time (17%).


Next Steps

Past Performance

How has Medpace Holdings performed over the past 5 years?

72.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: MEDP's earnings have grown significantly by 72.5% per year over the past 5 years.

Accelerating Growth: MEDP's earnings growth over the past year (70%) is below its 5-year average (72.5% per year).

Earnings vs Industry: MEDP earnings growth over the past year (70%) exceeded the Life Sciences industry 45%.


Return on Equity

High ROE: MEDP's Return on Equity (13.5%) is considered low.


Return on Assets

ROA vs Industry: MEDP has a higher Return on Assets than the Life Sciences industry average last year.


Return on Capital Employed

ROCE Improving: MEDP has significantly improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is Medpace Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: MEDP's short term assets ($194.3M) do not cover its short term liabilities ($296.1M)

Long Term Liabilities: MEDP's short term assets (194.3M) exceeds its long term liabilities (62.7M)


Debt to Equity History and Analysis

Debt Level: MEDP is debt free.

Reducing Debt: MEDP had no debt 5 years ago.

Debt Coverage: MEDP has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: MEDP has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: MEDP has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if MEDP's debt is covered by short term assets.


Next Steps

Dividend

What is Medpace Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.7%industryaverage0.4%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate MEDP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MEDP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if MEDP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MEDP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MEDP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Medpace Holdings's salary, the management and board of directors tenure and is there insider trading?

7.9yrs

Average management tenure


CEO

August Troendle (63yo)

27.3yrs

Tenure

US$528,290

Compensation

Dr. August James Troendle, M.D. has been the Chairman, Chief Executive Officer and President at Medpace Holdings, Inc. since July 1992. Dr. Troendle founded Medpace Holdings, Inc. in July 1992. He founded  ...


CEO Compensation Analysis

Compensation vs. Market: August's total compensation ($USD528.29K) is below average for companies of similar size in the US market ($USD5.11M).

Compensation vs Earnings: August's compensation has been consistent with company performance over the past year.


Management Age and Tenure

7.9yrs

Average Tenure

53yo

Average Age

Experienced Management: MEDP's management team is seasoned and experienced (7.9 years average tenure).


Board Age and Tenure

2.2yrs

Average Tenure

63yo

Average Age

Experienced Board: MEDP's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Eric Humes

    Executive Director of Quality Assurance

    • Tenure: 0yrs
  • August Troendle (63yo)

    Chairman

    • Tenure: 27.3yrs
    • Compensation: US$528.29k
  • Weimin Gai

    Senior Vice President of Biometrics

    • Tenure: 0yrs
  • Susan Burwig (56yo)

    Executive Vice President of Operations

    • Tenure: 2.8yrs
    • Compensation: US$729.75k
  • Yong-Xi Li

    Executive Director of Medpace Bioanalytical Laboratories - Medpace Labs

    • Tenure: 0yrs
  • Todd Meyers

    Vice President of Business Development & Marketing

    • Tenure: 0yrs
  • Jesse Geiger (45yo)

    CFO & Chief Operating Officer of Laboratory Operations

    • Tenure: 8.6yrs
    • Compensation: US$676.54k
  • Stephen Ewald (50yo)

    General Counsel & Corporate Secretary

    • Tenure: 7.3yrs
  • Daniel O'Leary

    Senior Vice President of Medical Department

    • Tenure: 0yrs
  • Kevin Brady

    Executive Director of Finance

    • Tenure: 0yrs

Board Members

  • Fred Davenport (67yo)

    Director

    • Tenure: 1.2yrs
    • Compensation: US$86.75k
  • Neal McCarthy (59yo)

    Director

    • Tenure: 1.2yrs
    • Compensation: US$83.87k
  • August Troendle (63yo)

    Chairman

    • Tenure: 27.3yrs
    • Compensation: US$528.29k
  • Rocky Kraft (49yo)

    Director

    • Tenure: 3.3yrs
    • Compensation: US$144.99k
  • Brian Carley (65yo)

    Director

    • Tenure: 3.3yrs
    • Compensation: US$149.99k
  • Ashley Keating

    Director

    • Tenure: 0.4yrs

Company Information

Medpace Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Medpace Holdings, Inc.
  • Ticker: MEDP
  • Exchange: NasdaqGS
  • Founded: 1992
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.782b
  • Shares outstanding: 35.70m
  • Website: https://www.medpace.com

Number of Employees


Location

  • Medpace Holdings, Inc.
  • 5375 Medpace Way
  • Cincinnati
  • Ohio
  • 45227
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
01PDB (Deutsche Boerse AG)YesCommon StockDEEURAug 2016
MEDPNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDAug 2016
MEDP *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNAug 2016

Biography

Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industrie ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 00:45
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.